Last reviewed · How we verify
DMT continuation
DMT continuation refers to the ongoing administration of disease-modifying therapy in multiple sclerosis patients to maintain therapeutic benefit and prevent disease progression.
DMT continuation refers to the ongoing administration of disease-modifying therapy in multiple sclerosis patients to maintain therapeutic benefit and prevent disease progression. Used for Multiple sclerosis (continuation of disease-modifying therapy).
At a glance
| Generic name | DMT continuation |
|---|---|
| Sponsor | Rennes University Hospital |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
This represents a continuation phase study evaluating the sustained efficacy and safety of a disease-modifying treatment (DMT) in multiple sclerosis. The specific mechanism depends on the underlying DMT being continued, which could involve immunomodulation, immune suppression, or other pathways targeting MS pathophysiology. Phase 3 continuation studies typically assess long-term outcomes and tolerability in patients who have completed initial treatment phases.
Approved indications
- Multiple sclerosis (continuation of disease-modifying therapy)
Common side effects
Key clinical trials
- Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) (PHASE3)
- Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study
- Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) (PHASE3)
- Dance and Movement Therapy in Patients With Schizophrenia (NA)
- Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DMT continuation CI brief — competitive landscape report
- DMT continuation updates RSS · CI watch RSS
- Rennes University Hospital portfolio CI